(Q36759372)

English

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

scientific article published on 12 November 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

phase I clinical trial

0 references

18

object named as

Elaine Mardis

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Zachary L Skidmore

object named as

Zachary L Skidmore

8

0 references

object named as

Avinash Ramu

10

0 references

Foluso Ademuyiwa

object named as

Foluso Ademuyiwa

4

0 references

7

object named as

Obi L Griffith

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Malachi Griffith

6

object named as

Malachi Griffith

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

16

object named as

Jeremy Hoog

1 reference

Europe PubMed Central

16 August 2017

PMC publication ID

11

object named as

Lee Trani

1 reference

Europe PubMed Central

16 August 2017

PMC publication ID

author name string

Cynthia X Ma

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jingqin Luo

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Michael Naughton

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Rama Suresh

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Nicholas C Spies

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Timothy Pluard

12

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Gayathri Nagaraj

13

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Shana Thomas

14

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Zhanfang Guo

15

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jing Han

17

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Craig Lockhart

19

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Matthew J Ellis

20

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

12 November 2015

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

22

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1583-1591

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Genome Modeling System: A Knowledge Management Platform for Genomics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

PI3K and cancer: lessons, challenges and opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Comprehensive molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Whole-genome analysis informs breast cancer response to aromatase inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

SomaticSniper: identification of somatic point mutations in whole genome sequencing data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Fast and accurate short read alignment with Burrows-Wheeler transform

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

29 September 2017

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

5 September 2018

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4818722

5 September 2018

Identifiers

10.1158/1078-0432.CCR-15-1745

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36759372&oldid=2119915747"